13.11.2018 • News

Lanxess and Standard Lithium in Battery Project

Lanxess and Standard Lithium in Battery Project (c) Predrag...
Lanxess and Standard Lithium in Battery Project (c) Predrag Novakovic/iStockphoto

German specialty chemicals producer Lanxess and Canada’s Standard Lithium are mulling plans for a joint venture to commercially produce battery grade lithium from brine at El Dorado, Arkansas. Technical and economic feasibility studies for the US project are in progress.

Lanxess, which regards itself as one of the world's leading manufacturers of bromine, bromine precursors and brominated flame retardants, already operates three plants for production of bromine products from brine in El Dorado. Standard Lithium has developed a new process for the extraction of high-purity lithium directly from brines.

Under the new collaboration plans, Lanxess would grant Standard Lithium access to its existing infrastructure at the site, where would the Canadian company would build and operate a pilot plant.

Bromine and bromine-based intermediates are used as building blocks for the production of highly complex molecules and used in many applications, including flame retardants, agrochemicals, pharmaceuticals, fine chemicals, butyl rubber, polymers and biocides.

"For us, innovation also means developing new uses for existing products. The cooperation with Standard Lithium is still at a very early stage, but could open up exciting prospects for us in a trend-setting industry," said Lanxess CEO Matthias Zachert.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

29 April 2026 | This webinar explores how chemical industry organizations can design a digital‑ and AI‑ready operating model focused on clarity, usability, and measurable value.

Interview

Navigating Uncertainty and Driving Innovation
Meeting Pharma’s Demand for Speed, Reliability, and Flexibility

Navigating Uncertainty and Driving Innovation

Axplora CCO Arul Ramadurai discusses navigating industry uncertainty, building strategic partnerships, and advancing flexible pharmaceutical manufacturing

most read